2. Search Result
Search Result
Results for "

her2-expressing tumors

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

2

Fluorescent Dyes

1

Peptides

2

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-164992
    Trastuzumab vedotin
    2 Publications Verification

    MRG002; Trastuzumab MMAE

    		 Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin Cancer
    Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
    Trastuzumab vedotin
  • HY-W614269
    DOTA-GA(tBu)4

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTA-GA(tBu)4 stabilizes the attachment of radiometals to ligands. DOTA-GA(tBu)4 improves the biodistribution of radiolabeled second-generation Affibody molecules by increasing their net negative charge and reducing hepatic uptake, leading to enhanced tumor-to-blood and tumor-to-liver ratios. DOTA-GA(tBu)4 targets HER2>-expressing breast and gastrointestinal cancer .
    DOTA-GA(tBu)4
  • HY-P99896
    Runimotamab

    BTRC-4017A; RG-6194

    		 EGFR CD3 Cancer
    Runimotamab (BTRC-4017A) is a HER2 and CD3 T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Runimotamab
  • HY-P9994
    Pertuzumab zuvotolimod

    SBT6050

    		 Antibody-Drug Conjugates (ADCs) EGFR Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    Pertuzumab zuvotolimod (SBT6050) is an anti-HER2 antibody-drug conjugate (ADC). Pertuzumab zuvotolimod is composed of a humanized anti-HER2 antibody (Pertuzumab) (HY-P9912A), a linker, a TLR8 agonist payload, and the drug-linker conjugate for ADC is Zuvotolimod (HY-145620). Pertuzumab zuvotolimod potently induces multiple anti-tumor immune activities through the direct activation myeloid cells and the subsequent induction of T and NK cell cytolytic activity. Pertuzumab zuvotolimod can be used for HER2-expressing solid tumors research .
    Pertuzumab zuvotolimod
  • HY-W540123
    Fmoc-PNA-A(Bhoc)-OH

    		Biochemical Assay Reagents Cancer
    Fmoc-PNA-A(Bhoc)-OH is a protected peptide nucleic acid (PNA) monomer carrying an adenine base. Fmoc-PNA-A(Bhoc)-OH contains Fmoc and benzhydryloxycarbonyl (Bhoc) protecting groups, and serves as a standard building block designed specifically for solid-phase PNA synthesis. Fmoc-PNA-A(Bhoc)-OH can be efficiently used to synthesize PNA-based sequence-specific hybridization probes. These probes have broad applications in molecular biology research; for example, they can be used in HER2-expressing tumor-related studies, providing tools for disease diagnosis and mechanism exploration .
    Fmoc-PNA-A(Bhoc)-OH
  • HY-183253
    DL149

    		Drug-Linker Conjugates for ADC Eukaryotic Initiation Factor (eIF) EGFR Cancer
    DL149 is a component of an antibody-drug conjugate (ADC) formed by conjugating the eIF4A inhibitor FD236 (HY-186186) with an ADC linker, and exhibits potential antitumor activity. DL149 can bind to an anti-HER2 antibody to form a complete ADC molecule, which precisely binds to the HER2 receptor on the surface of tumor cells. After internalization into cells, it releases the eIF4A inhibitor payload. DL149 irreversibly blocks the mRNA translation process in tumor cells, thereby inhibiting tumor cell proliferation and inducing their death. DL149 exhibits in vivo antitumor activity in the SK-OV-3 xenograft tumor model, and can be used for the research of HER2-positive solid tumors .
    DL149

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: